Maribavir
Key facts
| Active substance |
Maribavir
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/42/2009
|
| PIP number |
Maribavir
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Cytomegaloviral disease
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
ViroPharma SPRL
E-mail: john.watson@viropharma.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|